Clinical trials · source year
55 selected, source-linked clinical trial records dated 2017. This is selective source coverage, not a complete timeline.
55 selected records.
11 connected profiles.
55 distinct public records.
Cited chronology
Teriparatide
PeptideScanner retained ClinicalTrials.gov record NCT01705587 at 2026-07-30T21:22:00.252Z. Its registry update date was 2017-12-12, and PeptideScanner's reviewed identity mapping was teriparatide.
Source: ClinicalTrials.gov ↗
Semaglutide
PeptideScanner retained ClinicalTrials.gov record NCT02079870 at 2026-07-30T21:22:00.245Z. Its registry update date was 2017-12-02, and PeptideScanner's reviewed identity mapping was semaglutide.
Source: ClinicalTrials.gov ↗
Exenatide
PeptideScanner retained ClinicalTrials.gov record NCT01588418 at 2026-07-30T21:22:00.248Z. Its registry update date was 2017-11-24, and PeptideScanner's reviewed identity mapping was exenatide.
Source: ClinicalTrials.gov ↗
Leuprolide
PeptideScanner retained ClinicalTrials.gov record NCT01762943 at 2026-07-30T21:22:00.263Z. Its registry update date was 2017-11-20, and PeptideScanner's reviewed identity mapping was leuprolide.
Source: ClinicalTrials.gov ↗
Octreotide
PeptideScanner retained ClinicalTrials.gov record NCT03061604 at 2026-07-30T21:22:00.250Z. Its registry update date was 2017-11-14, and PeptideScanner's reviewed identity mapping was octreotide.
Source: ClinicalTrials.gov ↗
Liraglutide
PeptideScanner retained ClinicalTrials.gov record NCT00422058 at 2026-07-30T21:22:00.247Z. Its registry update date was 2017-11-01, and PeptideScanner's reviewed identity mapping was liraglutide.
Source: ClinicalTrials.gov ↗
Liraglutide
PeptideScanner retained ClinicalTrials.gov record NCT00781937 at 2026-07-30T21:22:00.250Z. Its registry update date was 2017-11-01, and PeptideScanner's reviewed identity mapping was liraglutide.
Source: ClinicalTrials.gov ↗
Liraglutide
PeptideScanner retained ClinicalTrials.gov record NCT01557166 at 2026-07-30T21:22:00.252Z. Its registry update date was 2017-11-01, and PeptideScanner's reviewed identity mapping was liraglutide.
Source: ClinicalTrials.gov ↗
Tesamorelin
PeptideScanner retained ClinicalTrials.gov record NCT01263717 at 2026-07-30T21:22:00.255Z. Its registry update date was 2017-10-30, and PeptideScanner's reviewed identity mapping was tesamorelin.
Source: ClinicalTrials.gov ↗
Liraglutide
PeptideScanner retained ClinicalTrials.gov record NCT02647944 at 2026-07-30T21:22:00.265Z. Its registry update date was 2017-10-27, and PeptideScanner's reviewed identity mapping was liraglutide.
Source: ClinicalTrials.gov ↗
Lanreotide
PeptideScanner retained ClinicalTrials.gov record NCT02351128 at 2026-07-30T21:22:00.252Z. Its registry update date was 2017-10-18, and PeptideScanner's reviewed identity mapping was lanreotide.
Source: ClinicalTrials.gov ↗
Leuprolide
PeptideScanner retained ClinicalTrials.gov record NCT00589472 at 2026-07-30T21:22:00.251Z. Its registry update date was 2017-10-06, and PeptideScanner's reviewed identity mapping was leuprolide.
Source: ClinicalTrials.gov ↗
Exenatide
PeptideScanner retained ClinicalTrials.gov record NCT01969149 at 2026-07-30T21:22:00.262Z. Its registry update date was 2017-10-06, and PeptideScanner's reviewed identity mapping was exenatide.
Source: ClinicalTrials.gov ↗
Exenatide
PeptideScanner retained ClinicalTrials.gov record NCT00456885 at 2026-07-30T21:23:14.762Z. Its registry update date was 2017-09-11, and PeptideScanner's reviewed identity mapping was exenatide.
Source: ClinicalTrials.gov ↗
Liraglutide
PeptideScanner retained ClinicalTrials.gov record NCT02321878 at 2026-07-30T21:23:14.758Z. Its registry update date was 2017-09-01, and PeptideScanner's reviewed identity mapping was liraglutide.
Source: ClinicalTrials.gov ↗
Glucagon
PeptideScanner retained ClinicalTrials.gov record NCT02516150 at 2026-07-30T21:23:14.758Z. Its registry update date was 2017-08-31, and PeptideScanner's reviewed identity mapping was glucagon.
Source: ClinicalTrials.gov ↗
Octreotide
PeptideScanner retained ClinicalTrials.gov record NCT02474914 at 2026-07-30T21:23:14.756Z. Its registry update date was 2017-08-22, and PeptideScanner's reviewed identity mapping was octreotide.
Source: ClinicalTrials.gov ↗
Teriparatide
PeptideScanner retained ClinicalTrials.gov record NCT01153425 at 2026-07-30T21:23:14.757Z. Its registry update date was 2017-08-04, and PeptideScanner's reviewed identity mapping was teriparatide.
Source: ClinicalTrials.gov ↗
Liraglutide
PeptideScanner retained ClinicalTrials.gov record NCT00978393 at 2026-07-30T21:23:14.756Z. Its registry update date was 2017-07-27, and PeptideScanner's reviewed identity mapping was liraglutide.
Source: ClinicalTrials.gov ↗
Octreotide
PeptideScanner retained ClinicalTrials.gov record NCT00600886 at 2026-07-30T21:23:14.761Z. Its registry update date was 2017-07-02, and PeptideScanner's reviewed identity mapping was octreotide.
Source: ClinicalTrials.gov ↗
Linaclotide
PeptideScanner retained ClinicalTrials.gov record NCT02291679 at 2026-07-30T21:24:24.231Z. Its registry update date was 2017-06-15, and PeptideScanner's reviewed identity mapping was linaclotide.
Source: ClinicalTrials.gov ↗
Leuprolide
PeptideScanner retained ClinicalTrials.gov record NCT01023061 at 2026-07-30T21:24:24.232Z. Its registry update date was 2017-06-06, and PeptideScanner's reviewed identity mapping was leuprolide.
Source: ClinicalTrials.gov ↗
Leuprolide
PeptideScanner retained ClinicalTrials.gov record NCT00225420 at 2026-07-30T21:24:24.228Z. Its registry update date was 2017-06-01, and PeptideScanner's reviewed identity mapping was leuprolide.
Source: ClinicalTrials.gov ↗
Liraglutide
PeptideScanner retained ClinicalTrials.gov record NCT01562678 at 2026-07-30T21:24:24.231Z. Its registry update date was 2017-05-31, and PeptideScanner's reviewed identity mapping was liraglutide.
Source: ClinicalTrials.gov ↗
Leuprolide
PeptideScanner retained ClinicalTrials.gov record NCT01431391 at 2026-07-30T21:24:24.227Z. Its registry update date was 2017-05-30, and PeptideScanner's reviewed identity mapping was leuprolide.
Source: ClinicalTrials.gov ↗
Leuprolide
PeptideScanner retained ClinicalTrials.gov record NCT02107391 at 2026-07-30T21:24:24.227Z. Its registry update date was 2017-05-24, and PeptideScanner's reviewed identity mapping was leuprolide.
Source: ClinicalTrials.gov ↗
Leuprolide
PeptideScanner retained ClinicalTrials.gov record NCT00170157 at 2026-07-30T21:24:24.228Z. Its registry update date was 2017-05-15, and PeptideScanner's reviewed identity mapping was leuprolide.
Source: ClinicalTrials.gov ↗
Teriparatide
PeptideScanner retained ClinicalTrials.gov record NCT00759772 at 2026-07-30T21:24:24.229Z. Its registry update date was 2017-05-11, and PeptideScanner's reviewed identity mapping was teriparatide.
Source: ClinicalTrials.gov ↗
Liraglutide
PeptideScanner retained ClinicalTrials.gov record NCT01739049 at 2026-07-30T21:24:24.225Z. Its registry update date was 2017-05-04, and PeptideScanner's reviewed identity mapping was liraglutide.
Source: ClinicalTrials.gov ↗
Ipamorelin
PeptideScanner retained ClinicalTrials.gov record NCT00672074 at 2026-07-30T21:24:24.228Z. Its registry update date was 2017-04-14, and PeptideScanner's reviewed identity mapping was ipamorelin.
Source: ClinicalTrials.gov ↗
Ipamorelin
PeptideScanner retained ClinicalTrials.gov record NCT01280344 at 2026-07-30T21:24:24.229Z. Its registry update date was 2017-04-13, and PeptideScanner's reviewed identity mapping was ipamorelin.
Source: ClinicalTrials.gov ↗
Octreotide
PeptideScanner retained ClinicalTrials.gov record NCT00182754 at 2026-07-30T21:24:24.234Z. Its registry update date was 2017-04-11, and PeptideScanner's reviewed identity mapping was octreotide.
Source: ClinicalTrials.gov ↗
Exenatide
PeptideScanner retained ClinicalTrials.gov record NCT00650546 at 2026-07-30T21:24:24.230Z. Its registry update date was 2017-04-11, and PeptideScanner's reviewed identity mapping was exenatide.
Source: ClinicalTrials.gov ↗
Teriparatide
PeptideScanner retained ClinicalTrials.gov record NCT01400516 at 2026-07-30T21:24:24.225Z. Its registry update date was 2017-04-11, and PeptideScanner's reviewed identity mapping was teriparatide.
Source: ClinicalTrials.gov ↗
Leuprolide
PeptideScanner retained ClinicalTrials.gov record NCT00380406 at 2026-07-30T21:24:24.229Z. Its registry update date was 2017-04-05, and PeptideScanner's reviewed identity mapping was leuprolide.
Source: ClinicalTrials.gov ↗
Semaglutide
PeptideScanner retained ClinicalTrials.gov record NCT02022254 at 2026-07-30T21:24:24.232Z. Its registry update date was 2017-04-04, and PeptideScanner's reviewed identity mapping was semaglutide.
Source: ClinicalTrials.gov ↗
Octreotide
PeptideScanner retained ClinicalTrials.gov record NCT00332969 at 2026-07-30T21:25:36.783Z. Its registry update date was 2017-03-31, and PeptideScanner's reviewed identity mapping was octreotide.
Source: ClinicalTrials.gov ↗
Liraglutide
PeptideScanner retained ClinicalTrials.gov record NCT00318461 at 2026-07-30T21:25:37.025Z. Its registry update date was 2017-03-07, and PeptideScanner's reviewed identity mapping was liraglutide.
Source: ClinicalTrials.gov ↗
Exenatide
PeptideScanner retained ClinicalTrials.gov record NCT01484873 at 2026-07-30T21:25:36.820Z. Its registry update date was 2017-03-03, and PeptideScanner's reviewed identity mapping was exenatide.
Source: ClinicalTrials.gov ↗
Exenatide
PeptideScanner retained ClinicalTrials.gov record NCT00855439 at 2026-07-30T21:25:36.764Z. Its registry update date was 2017-03-01, and PeptideScanner's reviewed identity mapping was exenatide.
Source: ClinicalTrials.gov ↗
Liraglutide
PeptideScanner retained ClinicalTrials.gov record NCT03068065 at 2026-07-30T21:25:36.832Z. Its registry update date was 2017-03-01, and PeptideScanner's reviewed identity mapping was liraglutide.
Source: ClinicalTrials.gov ↗
Liraglutide
PeptideScanner retained ClinicalTrials.gov record NCT01518101 at 2026-07-30T21:25:36.782Z. Its registry update date was 2017-02-27, and PeptideScanner's reviewed identity mapping was liraglutide.
Source: ClinicalTrials.gov ↗
Octreotide
PeptideScanner retained ClinicalTrials.gov record NCT00171886 at 2026-07-30T21:25:36.764Z. Its registry update date was 2017-02-24, and PeptideScanner's reviewed identity mapping was octreotide.
Source: ClinicalTrials.gov ↗
Liraglutide
PeptideScanner retained ClinicalTrials.gov record NCT01128894 at 2026-07-30T21:25:36.852Z. Its registry update date was 2017-02-23, and PeptideScanner's reviewed identity mapping was liraglutide.
Source: ClinicalTrials.gov ↗
Exenatide
PeptideScanner retained ClinicalTrials.gov record NCT02325960 at 2026-07-30T21:25:37.027Z. Its registry update date was 2017-02-23, and PeptideScanner's reviewed identity mapping was exenatide.
Source: ClinicalTrials.gov ↗
Liraglutide
PeptideScanner retained ClinicalTrials.gov record NCT00873223 at 2026-07-30T21:25:36.788Z. Its registry update date was 2017-01-26, and PeptideScanner's reviewed identity mapping was liraglutide.
Source: ClinicalTrials.gov ↗
Liraglutide
PeptideScanner retained ClinicalTrials.gov record NCT01515592 at 2026-07-30T21:25:36.784Z. Its registry update date was 2017-01-25, and PeptideScanner's reviewed identity mapping was liraglutide.
Source: ClinicalTrials.gov ↗
Liraglutide
PeptideScanner retained ClinicalTrials.gov record NCT01516255 at 2026-07-30T21:25:36.817Z. Its registry update date was 2017-01-25, and PeptideScanner's reviewed identity mapping was liraglutide.
Source: ClinicalTrials.gov ↗
Liraglutide
PeptideScanner retained ClinicalTrials.gov record NCT01518166 at 2026-07-30T21:25:36.824Z. Its registry update date was 2017-01-25, and PeptideScanner's reviewed identity mapping was liraglutide.
Source: ClinicalTrials.gov ↗
Liraglutide
PeptideScanner retained ClinicalTrials.gov record NCT01620476 at 2026-07-30T21:25:37.025Z. Its registry update date was 2017-01-25, and PeptideScanner's reviewed identity mapping was liraglutide.
Source: ClinicalTrials.gov ↗
Liraglutide
PeptideScanner retained ClinicalTrials.gov record NCT01507272 at 2026-07-30T21:25:36.818Z. Its registry update date was 2017-01-24, and PeptideScanner's reviewed identity mapping was liraglutide.
Source: ClinicalTrials.gov ↗
Liraglutide
PeptideScanner retained ClinicalTrials.gov record NCT01507337 at 2026-07-30T21:25:36.779Z. Its registry update date was 2017-01-24, and PeptideScanner's reviewed identity mapping was liraglutide.
Source: ClinicalTrials.gov ↗
Liraglutide
PeptideScanner retained ClinicalTrials.gov record NCT01508806 at 2026-07-30T21:25:36.763Z. Its registry update date was 2017-01-24, and PeptideScanner's reviewed identity mapping was liraglutide.
Source: ClinicalTrials.gov ↗
Liraglutide
PeptideScanner retained ClinicalTrials.gov record NCT01620463 at 2026-07-30T21:25:36.783Z. Its registry update date was 2017-01-24, and PeptideScanner's reviewed identity mapping was liraglutide.
Source: ClinicalTrials.gov ↗
Octreotide
PeptideScanner retained ClinicalTrials.gov record NCT00223691 at 2026-07-30T21:25:36.812Z. Its registry update date was 2017-01-18, and PeptideScanner's reviewed identity mapping was octreotide.
Source: ClinicalTrials.gov ↗